ArticleClinical and experimental medicine2026
TMEM132A is associated with metabolic reprogramming, macrophage-oriented immune remodeling, and breast cancer progression.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of serum 5'tRF-Val as a promising non-invasive biomarker for early detection of esophageal cancer.Scientific reports · 2026Article
- miR-489 induces immunogenic cell death in breast cancer by targeting LAPTM4B.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Breast cancer progression reflects malignant cell programs coupled with immune remodeling. Biomarkers that connect tumor intrinsic states with microenvironmental interactions remain needed. We evaluated TMEM132A as a candidate marker in breast cancer. Bulk cohorts from The Cancer Genome Atlas, Genotype Tissue Expression, and Gene Expression Omnibus were analyzed to quantify TMEM132A expression, diagnostic discrimination, and associations with clinicopathologic features and survival. Single cell RNA sequencing and spatial transcriptomics localized TMEM132A across cell populations and tissue regions. Cell communication inference with correlation based validation and differential expression based enrichment, including GSEA and GSVA, were performed to characterize TMEM132A related biology. TMEM132A was consistently upregulated in tumors and separated tumor from normal tissue across datasets. High TMEM132A expression was associated with poorer outcomes and more advanced clinical categories. Single cell and spatial analyses localized TMEM132A mainly to malignant epithelial populations and tumor enriched regions, with reproducible links to macrophage related features. Cell communication analyses suggested that TMEM132A-positive malignant cells engage macrophage-associated signaling via the ANXA1–FPR3 and IL34–CSF1R axes; this inference was supported by correlation-based validation and is consistent with macrophage-oriented immune remodeling during breast cancer progression. TMEM132A-high tumors were enriched for cell cycle and DNA replication programs and showed higher activity in glycolysis, pentose phosphate pathway, oxidative phosphorylation, and pyrimidine metabolism. TMEM132A marks a malignant-associated state linked to adverse prognosis, proliferative and metabolic activation, and macrophage-oriented immune interactions, supporting its value for risk stratification and future mechanistic studies in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.